Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: Upcoming letter to shareholders Billwilke
2
Aug 12, 2008 09:07PM

We believe a meeting has occured between the PTO and Moore/TPL. We don't know if this was done face to face or by phone. Our thoughts are that Moore/TPL walked away from the meeting with a pretty good or very good idea of how accepting the examiner was of the responses from Moore/TPL on the rejections and perhaps have a good or very good feel for revalidation of the 148 and possibly the 336 at this time. This confidence in how the PTO will rule, may be the reason TPL is proceeding with more hiring to handle an expected increase in MMP licensing activity. This may have also played a role in the timing of PTSC's acquisition of Crossflo.

All the best,

Steve

Share
New Message
Please login to post a reply